樊嘉精准医学时代肝细胞癌的系统治疗专家视角(5)
[6]。
7小结与展望
中国肝癌的发病率和死亡率均超过全世界50%。近几年肝癌药物治疗继索拉非尼之后,仑伐替尼、瑞戈菲尼、卡博替尼、抗EGFR抑制剂、以ICI为核心的组合疗法层出不穷,促进肝癌药物治疗的进步。但是,由于肝癌的高度异质性,上述药物的整体有效率依然有限,预测疗效的分子靶标依然缺乏。精准的肝癌分子分型不仅有助于肝癌个体化诊断与治疗的决策、个性化的药物治疗,而且将极大加深临床医师对肝癌复杂性和异质性的理解,以便制订更加精准、有效的治疗策略。肝癌的系统治疗更是要与新的分子分型体系,临床病理信息紧密结合,同时要结合精准的分子标志物疗效预测,从而最大程度地提高肝癌患者生存率。
参考文献:
[1]YANG SZ, FENG XB, DONG JH. Surgical treatment of liver cancer guided by the concept of precision surgery[J]. J Pre Med, 2018, 33(3): 189-192, 196. (in Chinese)
杨世忠, 冯晓彬, 董家鸿. 精准外科理念指导下的肝癌外科治疗[J]. 精准医学杂志, 2018, 33(3): 189-192, 196.
[2]CHEN Z, WANG J. Consideration in the diagnosis and treatment of hepatic cancer based onevidence-based guidelines and precision medicine[J]. Lingnan Mod Clin Surg, 2018, 18(6): 615-617. (in Chinese)
陈政, 王捷. 基于循证指南和精准医学时代背景下肝癌诊疗的思考与总结[J]. 岭南现代临床外科, 2018, 18(6): 615-617.
[3]LU SC, GU WQ. Essentials of precision medicine in practice of surgical oncology for hepatobiliary tumors[J]. Chin J Hepatobiliary Surg, 2019, 25(1): 1-4. (in Chinese)
卢实春, 顾万清. 肝胆肿瘤外科治疗精准医学概要[J]. 中华肝胆外科杂志, 2019, 25(1): 1-4.
[4]SCHULZE K, NAULT JC, VILLANUEVA A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing[J]. J Hepatol, 2016, 65(5): 1031-1042.
[5]FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(): 1301-1314.
[6]GAO Q, ZHU H, DONG L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J]. Cell, 2019, 179(5): 1240.
[7]European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[8]HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380.
[9]LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359: 378-390.
[10]SCHULZE K, IMBEAUD S, LETOUZ E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J]. Nat Genet, 2015, 47(5): 505-511.
[11]GYAWALI B, PRASAD V. Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC[J]. Nat Rev Clin Oncol, 2017, 14(11): 653-654.
[12]SAWEY ET, CHANRION M, CAI C, et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening[J]. Cancer Cell, 2011, 19(3): 347-358.
[13]VILGRAIN V, PEREIRA H, ASSENAT E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1624-1636.
[14]CHENG AL, KANG YK, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
[15]BRUIX J, RAOUL JL, SHERMAN M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial[J]. J Hepatol, 2012, 57(4): 821-829.
[16]MARRERO JA, KUDO M, VENOOK AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study[J]. J Hepatol, 2016, 65(6): 1140-1147.
[17]FINN RS, MERLE P, GRANITO A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial[J]. J Hepatol, 2018, 69(2): 353-358.
[18]KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(): 1163-1173.
[19]CAINAP C, QIN S, HUANG WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial[J]. J Clin Oncol, 2015, 33(2): 172-179.
文章来源:《精准医学杂志》 网址: http://www.jzyxzz.cn/zonghexinwen/2020/1110/343.html